Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Maravai LifeSciences Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $1,181.1 Mil.
Maravai LifeSciences Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings EV-to-EBIT Related Terms
Maravai LifeSciences Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Maravai LifeSciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's EV-to-EBIT falls into.
Maravai LifeSciences Holdings's current Enterprise Value is $1,157.8 Mil.
Maravai LifeSciences Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings (MRVI) has a EV-to-EBIT of -10.29 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Maravai LifeSciences Holdings and its competitors. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 370 companies in the Biotechnology industry.
Is Maravai LifeSciences Holdings' EV-to-EBIT too high?
Maravai LifeSciences Holdings' current EV-to-EBIT is -10.29. Based on the distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maravai LifeSciences Holdings has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' EV-to-EBIT compare to LBRX and AVTX?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 370 companies for EV-to-EBIT. This places Maravai LifeSciences Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.03, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Maravai LifeSciences Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maravai LifeSciences Holdings's current EV-to-EBIT is -10.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.66, compared to a current price of $6.07 — trading 65.8% above its estimated fair value. The current EV-to-EBIT is -10.29. Maravai LifeSciences Holdings' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current EV-to-EBIT is -10.29 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of $6.07 is trading 65.8% above its estimated GF Value™ of $3.66.
GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.
Key valuation signals for MRVI:
EV-to-EBIT: -10.29
GF Value™: $3.66 vs. price of $6.07 (65.8% above fair value)
No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
58GF Score
Get the complete analysis for MRVI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRVI has been successfully added to your 
